Financial Data and Key Metrics Changes - Consolidated revenue for Q3 2025 increased by 3% year over year to $841 million [4] - Adjusted EBITDA grew 18% year over year to $375 million, with a record margin expansion across all three businesses [4][22] - Adjusted EPS increased by 35% year over year to $1.81 [4][22] - Net income rose by 78% year over year, with diluted net income per share increasing by 89% to $1.34 [22] Business Line Data and Key Metrics Changes - Gaming revenue increased by 38% year over year to $241 million, driven by strong gaming operations performance and contributions from Grover [9][22] - Recurring revenue grew by 14% year over year, accounting for approximately 69% of consolidated revenue [5][22] - iGaming revenue reached a record $86 million, up 16% year over year, with Adjusted EBITDA increasing by 42% to $34 million [17][22] Market Data and Key Metrics Changes - North American gaming machine sales remained strong with over 6,000 units shipped in the quarter [12] - The average daily revenue per unit in North America increased by 5% year over year, excluding Grover units [11] - The company entered the Nebraska Skill Game market and commenced trials in the Eastern European Dynamic Multi-game market [12] Company Strategy and Development Direction - The company is transitioning to a sole standard listing on the ASX, expected to enhance its profile in the gaming industry [5][6] - Focus remains on the integration of Grover into game development and technology platforms, with expectations for significant contributions in 2026 [6][39] - The company emphasizes a disciplined capital allocation strategy to create sustainable shareholder value [8][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver growth and profitability despite broader market challenges [20] - The gaming consumer market remains resilient, with expectations for continued strong performance in the fourth quarter [44] - Management highlighted the importance of not compromising long-term growth for short-term goals, focusing on quality earnings [37] Other Important Information - The company returned $111 million to shareholders through share repurchases during the quarter [5][30] - Operating cash flows generated in the quarter amounted to $184 million, with free cash flow increasing by 64% year over year to $136 million [26] - The company maintains a net debt leverage ratio of 3.3 times following the Grover acquisition [28] Q&A Session Summary Question: How does the company see the fourth quarter shaping up to hit 2025 guidance? - Management highlighted strong U.S. sales and contributions from Grover, indicating a predictable earnings outlook for Q4 [34][35] Question: Can you provide an update on Grover's integration and Indiana launch? - Grover added 229 games in the quarter, with successful integration into the Light & Wonder family and preparations for the Indiana market entry [38][39] Question: What drove the gaming margin improvement in Q3? - The gaming operations business saw significant growth, contributing to margin expansion, with expectations for continued momentum [40][41] Question: What is the outlook for iGaming and SciPlay? - iGaming showed strong growth driven by first-party content, while SciPlay is focused on stabilizing mature games like Jackpot Party to return to growth [53][48][59]

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these conditions [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers this year [1]

Financial Data and Key Metrics Changes - The company is experiencing a significant moment with transformational innovation, as noted by management, indicating a potential inflection point in growth [5] - Management aims to improve R&D as a percentage of sales from 8% to 9-10% without sacrificing EPS [10] - The company expects to deliver high single-digit EPS improvement starting in 2027, driven by margin improvements and operational efficiencies [40][60] Business Line Data and Key Metrics Changes - The company is focusing on high-growth areas such as cardiac ablation and AFib, with recent acquisitions like Afera contributing to growth [20][22] - The diabetes segment is expected to improve with the launch of two new sensors, which are anticipated to drive growth in the U.S. market [52][54] - CAS growth accelerated from about 30% to almost 50% from Q4 to Q1, with expectations to add an incremental $1 billion in revenue by early 2027 [63] Market Data and Key Metrics Changes - The U.S. TAVR business showed slight growth of above 6% in Q1, while international markets performed stronger [88] - The company is optimistic about the Ardian product line, anticipating significant market development following a favorable CMS announcement [80] Company Strategy and Development Direction - The management is committed to capitalizing on current growth drivers and accelerating margin improvement through M&A and portfolio optimization [6][20] - The company is not considering a wholesale breakup but is open to trimming down the portfolio if it enhances shareholder value [13][17] - The focus remains on innovation and operational improvements to drive differentiated top-line and bottom-line growth [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational foundation of the company, stating that past supply chain and quality issues are now behind them [20] - The company is optimistic about the back half of the year, expecting growth drivers to contribute positively to performance [50] - Management is closely monitoring the competitive landscape and is committed to evaluating the performance of key investments like the Hugo system [45] Other Important Information - The company is experiencing gross margin pressures due to tariffs and product mix but expects improvements as operational efficiencies are realized [31][34] - The management highlighted the importance of pricing strategies and cost management as key drivers for margin improvement [36][39] Q&A Session Summary Question: What areas does Elliott want to see improvement in? - Management indicated alignment with Elliott's focus on capitalizing on growth drivers and accelerating margin improvement through M&A and portfolio management [5][6] Question: Why has the company done less M&A compared to peers? - Management attributed the lower M&A activity to operational issues during COVID but expressed confidence in pursuing more deals moving forward [20][28] Question: How does the company plan to improve gross margins? - Management outlined strategies including better pricing management, cost controls, and innovation to drive gross margin improvements over time [36][39] Question: What is the outlook for the diabetes business? - The diabetes segment is expected to improve significantly with the launch of new sensors and a new durable pump, enhancing competitive positioning [52][54] Question: How does the company view the TAVR business? - Management remains confident in the TAVR franchise, citing recent product improvements and strong data supporting their market position [89]